{"result": "(\"entity\"<|>AGUA<|>ORGANIZATION<|>Water is a vital component in the treatment of patients, particularly in managing fluid intake and hydration levels.)\n##\n(\"entity\"<|>NATREMIA<|>EVENT<|>Natremia refers to the concentration of sodium in the blood, which is crucial for diagnosing and managing conditions like SIADH.)\n##\n(\"entity\"<|>HIPONATREMIA<|>EVENT<|>Hyponatremia is a condition characterized by low sodium levels in the blood, often a result of excessive water retention.)\n##\n(\"entity\"<|>NEFONA<|>ORGANIZATION<|>Nefona refers to the functional unit of the kidney responsible for filtering blood and producing urine.)\n##\n(\"entity\"<|>NUTRICIÓN ARTIFICIAL<|>ORGANIZATION<|>Artificial nutrition is a method of providing nutrients to patients who cannot eat by mouth, often used in conjunction with other treatments.)\n##\n(\"entity\"<|>CALCEMIA<|>EVENT<|>Calcemia refers to the concentration of calcium in the blood, which can be affected by various treatments and conditions.)\n##\n(\"entity\"<|>MAGNESEMIA<|>EVENT<|>Magnesemia refers to the concentration of magnesium in the blood, important for various physiological functions.)\n##\n(\"relationship\"<|>AGUA<|>HIPONATREMIA<|>Water intake is managed to prevent or treat hyponatremia in patients<|>7)\n##\n(\"relationship\"<|>NATREMIA<|>HIPONATREMIA<|>Monitoring natremia is essential for diagnosing and managing hyponatremia<|>9)\n##\n(\"relationship\"<|>FURSEMIDA<|>NUTRICIÓN ARTIFICIAL<|>Furosemida may interact with artificial nutrition, affecting fluid balance<|>4)\n##\n(\"relationship\"<|>NEFONA<|>FURSEMIDA<|>Furosemida acts on the nefona to promote the elimination of free water<|>8)\n##\n(\"relationship\"<|>CALCEMIA<|>FURSEMIDA<|>Furosemida can induce changes in calcemia due to its effects on renal function<|>6)\n##\n(\"relationship\"<|>MAGNESEMIA<|>FURSEMIDA<|>Furosemida may also affect magnesemia through its diuretic action<|>6)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: uciones de la medicación intravenosa,\n   líquidos orales, NP, agua en los alimentos y en la\n   NE, etc.) a menos de 0,5-1 litros al día. Únicamen-\n   te es válida en los pacientes que mantienen una\n   mínima capacidad renal de eliminar agua libre, la\n   cual se estima a través del cálculo de la fórmula de\n   Furst (NaU + KU/NaS)53. De forma que, pacientes\n   con una cifra inferior a 0,5 responderán a una RH\n   de 1 litro/día, mientras que aquellos con un valor\n   de la fórmula de Furst entre 0,5 y 1 pueden res-\n   ponder a una RH igual o menor a 0,5 litros. Los\n   pacientes en los que el resultado sea superior a 1\n   no van a responder a la RH, ya que su nefrona no\n   está eliminando agua libre de electrolitos. En este\n   caso se evitan los líquidos no necesarios para que\n   no empeore la hiponatremia, pero no para corre-\n   girla. La respuesta de un paciente determinado a\n   la RH puede ser cambiante y variar de un día para\n   otro. Se considerará una respuesta positiva cuan-\n   do la elevación de la NaS sea de un mínimo de 2\n   mmol/l cada día, durante al menos 2 días segui-\n   dos65. La RH no es práctica para todos los pacien-\n   tes, hay pacientes que no la toleran y a veces es\n   totalmente incompatible con la medicación endo-\n   venosa necesaria o con la nutrición artificial. Ade-\n   más, la RH a 0,5 l reduce la palatabilidad de la\n   comida y puede empeorar el estado nutricional\n   del paciente, en caso de prolongarse varios días39.\nb. Urea oral. La urea incrementa la eliminación renal\n   de agua libre y disminuye la natriuresis, lo que se\n   traduce en una elevación de la natremia sérica. En-\n   tre sus principales desventajas se encuentran la\n   mala palatabilidad que presenta, lo que disminuye\n   la adherencia diaria al tratamiento y el manteni-\n   miento de su efecto. Así como el desarrollo de azo-\n   temia con dosis altas. También se ha asociado con\n   una tasa elevada de hipercorrección de la natremia\n   en su uso inicial72. Otro inconveniente es que, al\n   inducir la diuresis osmótica (interfiriendo con la re-\n   absorción de agua en toda la nefrona), puede cau-\n   sar deshidratación franca con hipernatremia en\n   pacientes que no puedan beber agua libremente72,\n   73. Por otra parte, al no ser un fármaco de uso ha-\n---\n810      BLOQUE: SOPORTE NUTRICIONAL AVANZADO\n\nbitual para otras patologías, se desconocen su efectos secundarios. Experimentos con urea hace décadas revelaban que inducía descensos de la calcemia y la magnesemia, entre otras alteraciones, secundarias a un incremento en el aclaramiento renal de calcio y magnesio, inducidas por la diuresis osmótica que ejerce el fármaco74. Además de ello, en pacientes con SIADH no existe suficiente evidencia como para recomendar su uso75. Salvo en los pacientes que se sospeche un SIADH tipo D (mutación activadora del receptor V2), caracterizado por una ausencia de respuesta a los antagonistas del receptor V2 (conivaptán y tolvaptán)39, 45, 73.\n\nc. Furosemida. La administración de la furosemida en pacientes con SIADH y OsmU superior a 350 mOsm/kg, favorece la eliminación de agua libre modificando el gradiente osmótico entre la médula renal y el túbulo colector76, 77. Esta acción terapéutica se mantiene, siempre y cuando se garantice un correcto aporte de sodio a la médula renal. Para ello, se debe incrementar de forma significativa el consumo de sal (8-9 g de sal/día). La furosemida puede ser administrada tanto por vía intravenosa como por vía oral, en dosis habitualmente de 20 mg intravenosa cada 8 a 24 horas, o de 40 mg por vía oral cada 8 a 24 horas76, 77. La furosemida\n\nserá especialmente útil en pacientes hospitalizados, en los que la duración de su cuadro de SIADH se prevé limitada (por ejemplo, el SIADH secundario a neumonía)65. En la tabla 5 se muestra la probable duración del tratamiento del SIADH según la etiología y el riesgo relativo de SIADH crónico. Aunque este fármaco tiene también poca evidencia en el tratamiento del SIADH, al menos conocemos bien sus efectos secundarios, al ser de uso\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>FURSEMIDA<|>ORGANIZATION<|>Furosemida is a medication used to promote the elimination of free water in patients with SIADH, administered either intravenously or orally.)\n##\n(\"entity\"<|>SIADH<|>EVENT<|>Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH) is a condition that causes the body to retain water, leading to hyponatremia.)\n##\n(\"entity\"<|>UREA<|>ORGANIZATION<|>Urea is a compound used to increase renal elimination of free water and decrease natriuresis, but has poor palatability and potential side effects.)\n##\n(\"relationship\"<|>FURSEMIDA<|>SIADH<|>Furosemida is used to treat patients with SIADH by promoting the elimination of free water<|>8)\n##\n(\"relationship\"<|>UREA<|>SIADH<|>Urea is mentioned as a treatment option for SIADH, although it has significant drawbacks<|>5)\n<|COMPLETE|>"}]}